ACCEPT DECLINE
Change Visitor Type Sign up to our newsletter

Oxford Biotherapeutics

Invest in Oxford Biotherapeutics

Invest directly into OBT through our Co-Investor Circle.

Find out more

Oxford Biotherapeutics

By Oxford Capital |

“Cancer is one of the leading causes of death worldwide, with an estimated 27.5 million new cancer cases worldwide each year by 2040.”*.

The global burden of cancer is significant. Statistics forecast that 50% of people born after 1960 will most likely contract cancer in their lifetime*; and the cost of cancer care is set to exceed $156 billion by 2020. Successful drug medicines can therefore be enormously valuable to both patients and the owners of the drugs.

Oxford BioTherapeutics (“OBT”) is a well-established international biotechnology company, developing innovative, targeted anti-cancer medicines. Originally spun out of Oxford University’s Department of Glyco Sciences in 2004, it now employs 40 people and has offices in Milton Park, Oxfordshire and San Jose, California. It is widely considered one of the leading companies developing next generation cancer therapies, including Antibody-Drug Conjugates (ADC) and Immuno-Oncology (IO).

Immunotherapies discovered via OBT’s platform have potential to improve patient outcomes for a very wide range of cancers, and in a way which uses the body’s own immune system to deliver the drug, creating a treatment whereby only cancer cells are killed, whilst sparing normal cells. OBT can do this by leveraging its world leading proprietary cancer protein database to identify series of antennae which are unique to cancer cells, allowing the antibody to locate these receptors and deliver the cancer killing medicine.

The company has been capital efficient, having raised only £19m of venture funding to date, leveraged by £35m of partnership revenues which have been reinvested to develop its pipeline of exciting cancer drugs. The company has now reached a significant milestone in its development by securing an €800m non-dilutive investment from a major Italian Pharma, to take five identified OBT drugs through Phase I and Phase II clinical trials. The programme is already well advanced with the first drugs progressing in human clinical trials.

This current round of investment into OBT reflects a pre-money valuation of $100m. Market analysis shows that some small companies with only one lead product in early clinical trials have previously been acquired at valuations in excess of $500m by the major pharma, potentially representing a value uplift for investors should its cancer molecules show sign of anti-cancer activity in humans.

*Source: Cancer Research UK, 14th Nov 2018

Awards

  • BEST EIS
    FUND MANAGER
    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR
    WINNER 2013 AND 2005

  • INVESTOR OF
    THE YEAR
    WINNER IN 2012 AND 2013

  • MOST IMPACTFUL
    INVESTMENT
    WINNER 2017

  • BEST ANGEL
    SYNDICATE
    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY
    COMMENDED 2020

  • VC INVESTOR OF THE YEAR
    GIANT HEALTH AWARDS
    WINNER 2020

  • EXIT OF THE YEAR
    ONE TO WATCH
    2020